What the Switch to Trivalent Flu Vaccines in 2025–2026 Means for Flu Protection This Season

Bottom line: For the 2025–2026 flu season, flu shots in the United States protect against three influenza strains instead of four. Health officials say this change is not expected to reduce protection for most people this year—and vaccination remains the best way to lower your risk of severe flu.

The switch may sound technical, but it reflects how influenza viruses have changed in recent years. Here’s what happened, why it matters, and what families should know heading into the rest of this flu season.

What changed: From four strains to three

For more than a decade, most U.S. flu vaccines were quadrivalent, meaning they targeted four flu viruses:

Two influenza A strains (H1N1 and H3N2)
Two influenza B lineages (B/Victoria and B/Yamagata)

For the 2025–2026 season, vaccines are now trivalent. They include:

Two influenza A strains
One influenza B strain (B/Victoria lineage)

The B/Yamagata lineage has not been detected globally since early in the COVID-19 pandemic. Based on global surveillance data, public health agencies—including the World Health Organization (WHO) and the U.S. Food and Drug Administration (FDA)—recommended removing it from the vaccine composition.

Why was B/Yamagata removed?

According to WHO influenza surveillance reports and FDA vaccine strain selection guidance, the B/Yamagata lineage has not circulated in confirmed cases worldwide since 2020. Many experts believe it may no longer be circulating in humans.

Influenza vaccines are updated each year based on global monitoring data. When a strain no longer appears to be circulating, continuing to include it in the vaccine adds manufacturing complexity without clear benefit.

The FDA’s Vaccines and Related Biological Products Advisory Committee reviewed the surveillance evidence before recommending the shift to trivalent formulations for the U.S. market. The Centers for Disease Control and Prevention (CDC) continues to monitor for any re-emergence of B/Yamagata.

Does this mean less protection?

For most people, no.

Because B/Yamagata has not been detected for several years, removing it is not expected to reduce protection against currently circulating strains. The 2025–2026 vaccines still target:

H1N1 influenza A
H3N2 influenza A
B/Victoria influenza B

These are the strains responsible for seasonal illness in recent years.

Flu vaccine effectiveness varies year to year depending on how well the vaccine strains match circulating viruses. In general, CDC data show that flu vaccination reduces the risk of severe illness, hospitalization, and death—even when effectiveness against mild infection is moderate.

Who should still get vaccinated?

The CDC continues to recommend annual flu vaccination for everyone 6 months and older, with rare exceptions.

Vaccination is especially important for:

Adults 65 and older
Children under 5 (especially under 2)
Pregnant people
People with asthma, diabetes, heart disease, or weakened immune systems
Residents of nursing homes or long-term care facilities

For adults 65 and older, CDC guidance continues to prefer higher-dose or adjuvanted flu vaccines when available, because they tend to produce a stronger immune response in this age group.

What about safety?

Trivalent flu vaccines use the same manufacturing platforms as previous quadrivalent vaccines (egg-based, cell-based, and recombinant options). The removal of one influenza B strain does not introduce new safety concerns.

Flu vaccines are monitored through multiple safety systems, including the FDA’s MedWatch program and CDC’s Vaccine Adverse Event Reporting System (VAERS). Common side effects remain mild and short-lived, such as soreness at the injection site, low-grade fever, or fatigue.

Could B/Yamagata come back?

That is one area of uncertainty.

Global influenza surveillance continues through WHO and national public health systems. If B/Yamagata were to reappear and begin circulating again, vaccine strain recommendations could change in a future season.

For now, experts consider its return unlikely but not impossible. Influenza viruses are unpredictable, which is why surveillance and annual vaccine updates remain essential.

What this means for families, schools, and workplaces

Protection remains strong against circulating strains. The switch does not mean a weaker vaccine for this season.
Access and coverage are unchanged. Most private insurance plans, Medicare, and Medicaid cover flu vaccination without cost-sharing when given by an in-network provider.
Community protection still matters. Higher vaccination rates reduce spread in schools, workplaces, and long-term care settings.

Flu can cause serious complications, including pneumonia, worsening of chronic conditions, and hospitalization. Even in healthy adults, flu can mean a week or more of high fever, severe fatigue, and missed work or school.

When to seek medical care

Most flu cases can be managed at home with rest and fluids. However, seek medical care urgently for:

Difficulty breathing or chest pain
Persistent high fever
Confusion or severe weakness
Dehydration
Symptoms that improve, then suddenly worsen

Antiviral medications such as oseltamivir (Tamiflu) work best when started within 48 hours of symptom onset and are especially important for high-risk patients.

The bigger picture

The move to trivalent flu vaccines reflects how influenza viruses have evolved since the COVID-19 pandemic disrupted global circulation patterns. It is an example of how vaccine policy adapts to surveillance data.

For readers, the practical takeaway is simple: this year’s flu shot still targets the strains that are circulating and remains the best available protection against severe flu.

If you have not yet been vaccinated for the 2025–2026 season, it is not too late. Flu activity often continues into the spring.

Sources

This article is for general informational purposes only and is not medical advice. Research findings can be early, limited, or subject to change as new evidence emerges. For personal guidance, diagnosis, or treatment, consult a licensed clinician. For current outbreak or public health guidance, follow your local health department, the CDC, or another relevant public health authority.